An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the a αvβ3-selective angiogenesis imaging agent 99mTc-NC100692
An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the a αvβ3-selective angiogenesis imaging agent 99mTc-NC100692
复制标题
DOI：
10.3109/02841850903273974
复制
发表时间：
2010-02-01
期刊：
影响因子：
1.3
通讯作者：
McParland, Brian J.
中科院分区：
文献类型：
--
作者：
Axelsson, Rimma;Bach-Gansmo, Tore;McParland, Brian J.
背景：α (v) β(3)整合素是乳腺癌和肺癌血管新生相关的高表达膜蛋白之一。用Tc-99m-NC100692标记α (v) β(3)整合素为血管生成成像和恶性病变的存在提供了潜在的工具。目的：确定α (v) β(3)显像剂Tc-99m-NC100692在乳腺癌或肺癌患者中应用闪烁显像检测肝、肺、骨和脑转移病灶的可行性，并评估其安全性。材料和方法：在10个中心招募了25名患者，其中15名肺癌患者和10名乳腺癌患者。通过计算机断层扫描，磁共振成像或骨显像（即参考标准）新诊断转移。患者在注射后45分钟开始进行大约10-15分钟的全身扫描，在注射高达1100 MBq的Tc-99m-NC100692后75分钟开始进行大约30分钟的SPECT采集。在肝转移的情况下，注射后立即开始进行15分钟的动态采集。注射后2.5小时进行安全性测量，包括血液学、血清生化、凝血、尿液分析、生命体征、血氧测定、12导联心电图评估和体格检查。结果：在乳腺癌患者中，Tc-99m-NC100692显像检测到7例肝转移1例，5例肺转移4例，17例骨转移8例，1例脑转移1例。肺癌患者对应的数字分别为0 / 2、17 / 18、2 / 2、9 / 7。在整个随访期间，所有被调查的安全参数总体稳定。结论：Tc-99m-NC100692闪烁显像对乳腺癌、肺癌肺、脑转移灶的检测是可行的，对肝、骨转移灶的检测较差。Tc-99m-NC100692的使用是安全且耐受性良好的。
Background: The alpha(v)beta(3) integrin is one of the angiogenesis-related membrane proteins highly expressed on the neovasculature of breast cancer and lung carcinomas. Labeling of the alpha(v)beta(3) integrin with Tc-99m-NC100692 provides a potential tool for imaging angiogenesis and hence the presence of malignant lesions.Purpose: To determine the feasibility of detecting metastatic lesions in liver, lung, bone, and brain with scintigraphy using the alpha(v)beta(3)-avid imaging agent Tc-99m-NC100692 in patients with breast or lung cancer, and to assess its safety profile.Material and Methods: Twenty-five patients-15 with lung cancer and 10 with breast cancer-were recruited at 10 centers. Metastases were newly diagnosed by computed tomography, magnetic resonance imaging, or bone scintigraphy, i.e., the reference standard. Patients underwent whole-body scans of approximately 10-15 min duration beginning at 45 min post-injection and a SPECT acquisition of approximately 30 min beginning at 75 min after injection of up to 1100 MBq Tc-99m-NC100692. In case of liver metastases, dynamic acquisitions of 15 min were performed starting immediately post-injection. Safety measurements were performed up to 2.5 hours after injection and included hematology, serum biochemistry, coagulation, urine analysis, vital signs, oximetry, 12-lead ECG assessments, and a physical examination.Results: In patients with breast cancer, Tc-99m-NC100692 scintigraphy detected 1 of 7 liver, 4 of 5 lung, 8 of 17 bone, and 1 of 1 brain metastases. The corresponding numbers for lung cancer patients were 0 of 2, 17 of 18, 2 of 2, and 7 of 9. There was overall stability through the follow-up period for all investigated safety parameters.Conclusion: Scintigraphy with Tc-99m-NC100692 is feasible for detection of lung and brain metastases from breast and lung cancer, while the detection of liver and bone lesions is poor. The use of Tc-99m-NC100692 is safe and well tolerated.